Stock Events

Stock Events

Cyclacel Pharmaceuticals

€0.000000

94

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

12AugExpected

Q1 2026

Next

-0.03

0.3

0.63

0.97

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UXI4.MU. It's not an investment recommendation.

T. Rowe Price Group

Gladstone Investment

Gladstone Capital

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that competes in the development of drugs in areas such as oncology, where Cyclacel also operates.

Amgen is a biotech firm focusing on human therapeutics, including treatments for cancer, which puts it in direct competition with Cyclacel's oncology focus.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer treatments that compete with Cyclacel's product pipeline.

Pfizer is a global pharmaceutical corporation with a broad portfolio, including oncology, directly competing with Cyclacel's cancer-focused therapies.

Merck is known for its high-quality research and development in pharmaceuticals, including cancer drugs, making it a competitor to Cyclacel.

Novartis is a healthcare company that focuses on innovative medicines, with a strong emphasis on oncology, competing with Cyclacel in the cancer treatment market.

AbbVie operates in the discovery of new medicines, including for cancer, directly competing with Cyclacel's research and development in oncology.

AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including in oncology, competing with Cyclacel.

Roche Holding AG is a pioneer in healthcare, with a strong focus on pharmaceuticals and diagnostics in oncology, making it a competitor to Cyclacel.

Johnson & Johnson

Johnson & Johnson is a diverse healthcare company that has a pharmaceutical segment involved in the development of oncology treatments, competing with Cyclacel.

About

Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.

Show more...

CEO

Dr. Sing Ee Wong

Employees

12

Country

United States

ISIN

US23254L6039

Listings

0 Comments

Share your thoughts

FAQ

What is Cyclacel Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Cyclacel Pharmaceuticals stocks are traded under the ticker UXI4.MU.

When is the next Cyclacel Pharmaceuticals earnings date?▼

Cyclacel Pharmaceuticals is going to release the next earnings report on August 12, 2026.

What were Cyclacel Pharmaceuticals earnings last quarter?▼

UXI4.MU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does Cyclacel Pharmaceuticals have?▼

As of July 09, 2026, the company has 12 employees.

In which sector is Cyclacel Pharmaceuticals located?▼

Cyclacel Pharmaceuticals operates in the Health & Wellness sector.

When did Cyclacel Pharmaceuticals complete a stock split?▼

Cyclacel Pharmaceuticals has not had any recent stock splits.

Where is Cyclacel Pharmaceuticals headquartered?▼

Cyclacel Pharmaceuticals is headquartered in Kuala Lumpur, United States.